|
SEARCH
|
Research Papers by Venue
IPVS 2010
AASV 2010
BI Pre-AASV Health Seminar 2010
Leman 2009
AASV 2009
Leman 2008
IPVS 2008
AASV 2008
Leman 2007
IPVS 2010
Assessing the impact of maternally derived immunity on active immunization of pigs against PCV2 - Baysinger (view pdf)
Profile and agreement of dam and piglet PCV2 IFA titers - Baysinger (view pdf)
Visual-only evaluation of lung lesions as an alternative to palpation at necropsy - Baysinger (view pdf)
Impact of 1- OR 2-dose PCV2 vaccination regimens on wean-to-finish performance - Erlandson (view pdf)
AASV 2010
Assessing the impact of maternally derived immunity on active immunization of pigs against PCV2 - Baysinger (view pdf)
Performance benefits resulting from vaccination with Ingelvac CircoFLEX and/or Ingelvac PRRS MLV - Bretey (view pdf)
Head-to-head comparison of the level of protection and duration of immunity induced by different commercial PCV2 vaccines and an experimental live vaccine in PCV2 viremic pigs - Opriessnig (view pdf)
Visual-only evaluation of lung lesions as an alternative to palpation at necropsy - Taylor (view pdf)
BI Pre-AASV Health Seminar 2010
Performance benefits resulting from vaccination with Ingelvac CircoFLEX and/or Ingelvac PRRS MLV - Bretey (view pdf)
From the outside - Diaz (view pdf)
FLEX vaccinology - field application of 200 million doses in the U.S. - Holck (view pdf)
PRRS control: Has it changed post PCV2? - Jones (view pdf)
The quagmire of Enzootic Pneumonia: A view from the trenches - Lowe (view pdf)
Diagnosing clinical disease and subclinical infections in a vaccinated population - Schwartz (view pdf)
Leman 2009
Assessing the impact of maternally derived immunity on active immunization of pigs against PCV2 - Baysinger (view pdf)
Performance benefits resulting from vaccination with Ingelvac CircoFLEX and/or Ingelvac PRRS MLV - Bretey (view pdf)
Differential diagnosis of wasting and respiratory disease in PCV2 vaccinated populations of pigs - Diaz (view pdf)
Correlation between viral load and performance in PCV2 vaccinated or non-vaccinated pigs - Holck (view pdf)
Test characteristics when verifying Mycoplasma hyopneumoniae status in expected negative herds - Johnson (view pdf)
Comparative efficacy of three U.S. commercially available PCV2 vaccines using two-dose protocols in a commercial production system - Kelly (view pdf)
Comparison and economic evaluation of two PCV2 vaccination programs used in France - Lewandowski (view pdf)
Impact of PCV2 viremia in vaccinated and non-vaccinated pigs - Maass (view pdf)
AASV 2009
An innovative method for quantifying animal behavior responses to various immunization protocols - Bretey (view pdf)
Efficacy evaluation of a mixed Mycoplasma hyopneumoniae bacterin and a porcine circovirus type 2 vaccine - Eichmeyer (view pdf)
Diagnostic investigation into a reproductive failure associated with porcine parvovirus and porcine circovirus coinfection - McDowell (view pdf)
Field evaluation of Ingelvac CircoFLEX® on growth performance of pigs in a subclinical PCVAD herd - Verbeck (view pdf)
Leman 2008
Comparison of 1 and 2 dose vaccination regimens using three currently licensed
Mycoplasma hyopneumoniae vaccines in pigs - Baysinger (view pdf)
Efficacy of Ingelvac CircoFLEX® in a herd with subclinical PCVAD - Bretey (view pdf)
A case report on the dynamics of PCVAD in a PCV2-vaccinated herd over time - Cline (view pdf)
PCV2 infection dynamics under field conditions - Diaz (view pdf)
Efficacy of PCV2 vaccination of pigs, dams, or both on pig performance - Edler (view pdf)
Efficacy evaluation of a Mycoplasma hyopneumoniae bacterin in a mixture with a porcine circovirus type 2 vaccine - Eichmeyer (view pdf)
Willingness to approach behavior and feed disappearance of weaned pigs following vaccination with Mycoplasma hyopneumoniae vaccines - Fangman (view pdf)
Rapid onset of protection of two weeks for a novel one dose mycoplasma vaccine - Genzow (view pdf)
Efficacy of Ingelvac CircoFLEX® in face of maternal antibodies in a field trial in France - Grosse Liesner (view pdf)
A comparison of cross-sectional quantitative PCV2 PCR vs. individual animal quantitative PCV2 PCR and associated necropsy findings in 4 cases - Johnson (view pdf)
Performance of conventional health pigs vaccinated with Ingelvac MycoFLEX® or Suvaxyn® RespiFend - Kolb (view pdf)
Effect of PCV2 vaccination on growth performance in a subclinically affected herd - Orveillon (view pdf)
Ingelvac MycoFLEX® provides at least 26 weeks duration of immunity against M. hyopneumoniae - Piontkowski (view pdf)
Vaccination against PCV2 versus tissue homogenate in finishing phase - Ramirez (view pdf)
IPVS 2008
Impact of PCV2 vaccination for controlling Porcine Circovirus Associated Disease in a wean to finish production system - Arnold (view pdf)
Finishing mortality in a swine production system using different PCV2 vaccination protocols - Cardinal (view pdf)
An economic analysis of vaccinating pigs with Ingelvac CircoFLEX® to control uncomplicated clinical PCVAD - Cline (view pdf)
Seroprevalence of PCV2 in canadian swine herds - Cunningham (view pdf)
The impact of seroconversion following vaccination on the efficacy of PCV2 vaccination - Desrosiers (view pdf)
Efficacy evaluation of Mycoplasma hyopneumoniae bacterin in a mixture with a porcine circovirus type 2 vaccine - Eichmeyer (view pdf)
Willingness to approach behavior and feed disappearance of weaned pigs following vaccination with mycoplasma vaccines - Fangman (view pdf)
Rapid onset of protection of two weeks for a novel one dose mycoplasma vaccine - Genzow (view pdf)
Comparative performance of barns of pigs vaccinated or not vaccinated with a one-shot PCV2 vaccine - Gillespie (view pdf)
Vaccination provides superior control of PCV2 and PCVD - Gonzalez (view pdf)
Pork quality implications of PCV2 vaccines under normal conditions of use - Haas (view pdf)
A laboratory evaluation of the comparative injection site tissue reactivity of PCV2 vaccines - Kolb (view pdf)
Evaluation of Ingelvac CircoFLEX® efficacy in PCVAD affected farrow to finish farms in Korea - Lyoo (view pdf)
Effect of PCV2 vaccination on co-infections with porcine reproductive and respiratory syndrome virus and mycoplasma hyorhinis - Mette (view pdf)
Efficacy of a novel one-shot PCV2 vaccine under Japanese field conditions - Miyashita (view pdf)
Efficacy of a novel one-shot PCV2 vaccine in a multi-site production system in Southern Germany - Ritzmann (view pdf)
Lack of interference with maternal immunity and reduction of viremia in PCV2 vaccinated pigs - Ritzmann (view pdf)
Survey of PMWS impact on Brazilian swine companies - Schwartz (view pdf)
Performance of Ingelvac CircoFLEX® vaccinated pigs in a subclinical PCVAD herd - Young (view pdf)
AASV 2008
Impact of Ingelvac CircoFLEX® on PCV2 and porcine circovirus associated disease in a wean-to-finish production system - Arnold (view pdf)
Effects of porcine circovirus type 2 (PCV2) vaccination on mortality and average daily gain - Feldmann (view pdf)
Biologic and economic benefits of controlling subclinical PCVAD with vaccination - King (view pdf)
Comparative safety of PCV2 vaccines under field conditions - Kolb (view pdf)
Leman 2007
Injection site histologic lesions induced by commercial PCV2 piglet vaccines - Christmas (view pdf)
Efficacy of Ingelvac® CircoFLEX™ in pigs vaccinated at 3 or 6 weeks of age in a PRRS and Mycoplasma hyopneumoniae-negative production system - Cline (view pdf)
Results obtained with a novel PCV2 vaccine to protect multiple ages of pigs against PCVAD - Desrosiers (view pdf)
Correlation of serum PCV2 quantitative PCR test results to tissue IHC lesion scores and mortality rates - Diaz (view pdf)
PCV2 infection dynamics in vaccinated versus non-vaccinated groups of pigs from 5 farms - Diaz (view pdf)
The effect of vaccination against PRRSV on quantitative PCV2 PCR results - Genzow (view pdf)
Use of cross-sectional serum quantitative PCR for profiling PCV2 infection dynamics - Gonzalez (view pdf)
Controlling PCV2 and co-infections to reduce the impact of PCVAD in growing pigs - Jones (view pdf)
Comparative performance of barns of pigs vaccinated with Ingelvac CircoFLEX or other PCV2 vaccines - Kolb (view pdf)
An investigation into increased finishing mortality associated with uncomplicated PCV Type 2 infection: A case report - Wilt (view pdf)
Suvaxyn and RespiFend are registered trademarks of Fort Dodge Animal Health.
